Skip to main content
. 2021 Jul 13;148(5):1137–1146. doi: 10.1007/s00432-021-03681-9

Fig. 2.

Fig. 2

CTCs phenotypes in 60 treatment naïve NSCLC; A Percentage of E-CTCs, hybrid E/M-CTCs, M-CTCs for each patients (31 early stage and 29 advanced); B Distribution of total CTCs, E-CTCs, hybrid E/M-CTCs, M-CTCs in 60 NSCLC patients; C Distribution of E > m CTCs, e = m CTCs, e < M CTCs in 60 NSCLC patients